Loading…
Reported covered position: Vice President, Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2012 · second_quarter · Q2
Issues related to the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148), legislation related to expansion of the 340B Program, coverage of orphan drugs and S.3187, Food and Drug Administration Safety and Innovation Act (PDUFA reauthorization).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Q1
Source: Senate LDA
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
American Middle Class Tax (AMT) Relief Act of 2007
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
American Middle Class Tax (AMT) Relief Act of 2007
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
American Middle Class Tax (AMT) Relief Act of 2007
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Promoting Innovation and Access to Life-Saving Medicine Act
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Promoting Innovation and Access to Life-Saving Medicine Act
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments S. 301 - Physicians payments transparency, preemption of State law
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments Senate Finance Committee Health Reform Chairman's Mark S. 301 - Physicians payments transparency, preemption of State law
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments S. 301 - Physicians payments transparency, preemption of State law
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments Senate Finance Committee Health Reform Chairman's Mark S. 301 - Physicians payments transparency, preemption of State law
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Promoting Innovation and Access to Life-Saving Medicine Act
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Promoting Innovation and Access to Life-Saving Medicine Act
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
American Middle Class Tax (AMT) Relief Act of 2007
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
American Middle Class Tax (AMT) Relief Act of 2007
Client: LUNDBECK LLC · Firm: LUNDBECK LLC
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
PDUFA Reauthorization Implementation of 340b Orphan Provisions; health care technical concerns Orphan Health Reform Fee Exemption
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Q4
Drug Reimportation PDUFA Reauthorization Implementation of 340b Orphan Provisions; health care technical concerns Life Sciences research tax credit legislation Super Committee deficit reduction Orphan Health Reform Fee Exemption
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · third_quarter · Q3
Drug Reimportation PDUFA Reauthorization Implementation of 340b Orphan Provisions; health care technical concerns Life Sciences research tax credit legislation Orphan Health Reform Fee Exemption Orphan medicines incentives
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2011 · second_quarter · Q2
Drug Reimportation PDUFA Reauthorization Implementation of 340b Orphan Provisions; health care technical concerns Life Sciences research tax credit legislation Orphan Health Reform Fee Exemption Orphan medicines incentives
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2011 · first_quarter · Q1
Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug Implementation of 340b Orphan Provisions; health care technical concerns Life Sciences research tax credit legislation Orphan Health Reform Fee Exemption
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2010 · fourth_quarter · Q4
Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug Implementation of 340b Orphan Provisions; health care technical concerns Life Sciences research tax credit legislation Orphan Health Reform Fee Exemption
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2010 · fourth_quarter · Q4
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization, Office of Orphan Drug H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Q3
S. 525, H.R. 1298: Drug Reimportation PDUFA Reauthorization H.R. 5712: 340b Orphan Provisions; health care technical concerns H.R. 6165: Life Sciences research tax credit legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Q2
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation Issues related to the implementation of the Patient Protection and Affordable Care Act. 340b program language in H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010. H.R. 5712 -- health care technical corrections Issues related to orphan disease medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Q2
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform, orphan drugs, 340b S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - Physician payments PDUFA Reauthorization Orphan Drug Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Q1
H.R. 4872, H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - 340b, orphan drugs S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - pharmaceutical company fees S. 301 - physician payments PDUFA Reauthorization Orphan Drug Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Q4
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - health reform fee, 340b discounts S. 301 - physician payment transparency; preemption
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Q4
H.R. 3200, H.R. 3590, H.R. 3962, S. 1796 - health care reform S. 525, H.R. 1298 - drug reimportation H.R. 3590, S. 1796 - tax on pharmaceutical companies, 340b discounts S. 301 - physicians payments transparency; preemption
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Q3
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Monitor pricing investigation
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments Senate Finance Committee Health Reform Chairman's Mark S. 301 - Physicians payments transparency, preemption of State law
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Q2
Monitor pricing investigation
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments S. 301 - Physicians payments transparency, preemption of State law
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Q1
Pharmaceutical Pricing related to Senate inquiry.
Comparative Effectiveness Research, FDA Funding, Pharmaceutical Reimportation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · RR
Health care issues, including importation of pharmaceutical products, comparative effectiveness research, strengthening the FDA, and reauthorization of the Orphan Drug Act.
Health care issues, including importation of pharmaceutical products, comparative effectiveness research, strengthening the FDA, and reauthorization of the Orphan Drug Act.
Health care issues, including importation of pharmaceutical products, comparative effectiveness research, strengthening the FDA, and reauthorization of the Orphan Drug Act.